ACSL4 and colorectal carcinoma: Taken together, these results indicate that CDK1 physically binds to ACSL4 and increases the K48‐linked polyubiquitination of ACSL4 in a UBR5‐dependent manner, leading to ACSL4 protein degradation in oxaliplatin‐resistant CRC cells.